Regenxbio Inc. shares fall 1.85% intraday after publishing preclinical results for RGX-202 gene therapy.

Regenxbio Inc. declined 1.85% in intraday trading. The company announced the publication of preclinical results comparing a microdystrophin gene therapy construct that included the C-terminal (CT) domain to a microdystrophin construct without the CT domain. The results, published in peer-reviewed journals, showed that the microdystrophin with the CT domain improved functional benefit compared to the microdystrophin without, supporting the potential of RGX-202 to drive functional improvements in patients with Duchenne Muscular Dystrophy.